Althea hopes to be one of the first to supply the UK with medicinal cannabis

Althea hopes to be one of the first to supply the UK with medicinal cannabis

In late September last year, Althea (ASX: AGH) burst onto the ASX with a heavily subscribed IPO of $19.65 million.

The Melbourne-based medicinal cannabis company joined a suite of Australian companies vying for a slice of the fast-moving and ever-growing medicinal cannabis market.

Though the biggest sector right now is a close call between certain states in the USA and the nationally legalised recreational and medicinal market of Canada, there's plenty of other opportunities elsewhere.

Althea is looking to be one of the first suppliers of medicinal cannabis in the UK following the recent legalisation of medicinal cannabis in the country.

The Victorian company expects to be one of the first to supply the estimated 2.9 million UK cannabis patients with the drug.

Althea has already found considerable success in Australia with its niche formula that combines sales with education as well as on-the-ground medically trained sales teams helping cut through regulation and red tape.

The Australian company's push into the UK will be supported by Canadian giant Aphira, one of the world's largest cannabis companies with a market cap of $3 billion.

The two have entered into a cannabis product acquisition agreement to export medicinal cannabis into the UK, allowing Althea to focus on patient access and product distribution and education.

This deal will last until around 2020 when Althea's Australian production facility is expected to become operational.

Althea CEO Joshua Fegan says the opportunities in the UK are too hard to pass up, especially considering the legislative similarities between Australia and the UK.

"The UK's highly regulated framework for prescribing, supplying and possessing medicinal cannabis products is very similar to that of Australia," says Fegan.

"We know focusing on improving patient access to medicinal cannabis and educating medical practitioners on treatment is the key to establishing market share, so the UK market entry will be based on our three-phased business model successfully implemented in Australia."

Althea expects exports into the UK to commence from around mid-February.

Shares in Althea are up 4.48 per cent to $0.35 per share at 11.07am AEDT.

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

How P2C can help retailers maintain brand loyalty amid the supply chain crisis
Partner Content
With the ongoing supply chain crisis expected to continue throughout 2022, retailers ar...
Productsup
Advertisement

Related Stories

Trajan Group is on a mission to democratise healthcare, one merger at a time

Trajan Group is on a mission to democratise healthcare, one merger at a time

Since listing on the ASX in mid-2021, analytical sciences company T...

Online marketplace retailer MyDeal bucks late 2021 trend with record growth

Online marketplace retailer MyDeal bucks late 2021 trend with record growth

Leading online retail marketplace MyDeal.com.au (ASX: MYD) has reve...

UK private equity firm CapVest enters race for IVF giant Virtus Health with $649m bid

UK private equity firm CapVest enters race for IVF giant Virtus Health with $649m bid

Assisted reproductive services multinational Virtus Health (ASX: VR...

Peak bodies propose six-point plan to carry business through Omicron wave

Peak bodies propose six-point plan to carry business through Omicron wave

A coalition of Australia’s peak industry groups represen...